By Drug Target Review2024-05-22T12:00:53
The world’s first generation of human BBB organoids from hPSCs accurately replicated features of cerebral cavernous malformation.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2023-03-30T09:15:30
Sponsored by Halo Labs
2023-04-04T15:03:09
Sponsored by Agilent
2023-05-23T11:10:47
Sponsored by NanoTemper Technologies
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
2024-05-07T13:11:19
Sponsored by BellBrook Labs
Site powered by Webvision Cloud